P-182Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress. (20th June 2018) - Qin, S; Finn, R; Kudo, M; Meyer, T; Vogel, A; Ducreux, M; Macarulla, T; Tomasello, G; Boisserie, F; Hou, J; Li, C; Song, J; et al.